Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, CALIF., - March 15, 2010 - Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic a...
Mar 15, 2010 General Releases HTML PDF
Emeryville, Calif. - February 22, 2010 - Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and ...
Feb 22, 2010 General Releases HTML PDF
Emeryville, Calif., - August 18, 2009 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influ...
Aug 18, 2009 General Releases HTML PDF
EMERYVILLE, CALIF., August 18, 2009 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, t...
Aug 18, 2009 Financial Releases HTML PDF
Page: First Previous
...